Cancer immunology

3T Biosciences Expands Leadership Team With Bryan Irving, Ph.D., as Chief Scientific Officer to Progress Tumor-specific Therapies to Clinic

Retrieved on: 
Wednesday, October 25, 2023

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 /PRNewswire/ -- 3T Biosciences ("3T"), an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today announced the appointment of Bryan Irving, Ph.D., as chief scientific officer (CSO). In this role, Dr. Irving will be responsible for the company's scientific strategy and direction and will chair 3T's Scientific Advisory Board.

Key Points: 
  • In this role, Dr. Irving will be responsible for the company's scientific strategy and direction and will chair 3T's Scientific Advisory Board.
  • His work has focused primarily on exploring ways to modulate T-cell activity for therapeutic benefit in both oncology and autoimmune settings.
  • "3T shares my passion for innovation and has a culture of rigor and dedication to advancing novel therapies.
  • 3T Biosciences is an immunotherapy company focused on discovering and developing next-generation therapies with curative potential based on its immune-response-guided target discovery approach.

Immuno-Oncology360º Announces 2024 Keynotes and Featured Speakers for the 10th Annual NYC Meeting

Retrieved on: 
Thursday, October 19, 2023

NEW YORK, Oct. 19, 2023 /PRNewswire-PRWeb/ -- The Conference Forum today announced the launch of the 10th annual Immuno-Oncology 360º Summit (IO360°) taking place February 27-29, 2024, at New York Marriott Brooklyn Bridge, in Brooklyn, NY.

Key Points: 
  • The Conference Forum announced the IO360º Summit's 2024 keynotes and featured speakers for its 10th annual conference.
  • NEW YORK, Oct. 19, 2023 /PRNewswire-PRWeb/ -- The Conference Forum today announced the launch of the 10th annual Immuno-Oncology 360º Summit (IO360°) taking place February 27-29, 2024, at New York Marriott Brooklyn Bridge, in Brooklyn, NY.
  • The IO360° 2024 keynotes include:
    Genentech's Ira Mellman, PhD, VP, Cancer Immunology, will speak on the roles of data mining and AI, and other clinical and translational data, in discovery and trial design.
  • "The IO360º conference presents the latest data impacting the IO landscape and for the 10th annual event, we are pleased to announce the extraordinary leadership advancing this space.

ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production

Retrieved on: 
Tuesday, June 20, 2023

BioKey, Inc., a leading producer of dietary supplements in its GMP facility, is set to receive USD $1.0 million from Define Biotech Co. Ltd. amid increasing interest in mushroom-based nutritional supplements.

Key Points: 
  • BioKey, Inc., a leading producer of dietary supplements in its GMP facility, is set to receive USD $1.0 million from Define Biotech Co. Ltd. amid increasing interest in mushroom-based nutritional supplements.
  • This agreement marks the second year of a partnership that grants Define Biotech the right to distribute the nutritional supplement containing Maitake mushrooms in China and Taiwan.
  • The production of dietary supplements represents a viable revenue stream for ABVC BioPharma as they conduct clinical trials for their other drug candidates.
  • ABVC BioPharma believes developing these medicinal mushroom extracts as dietary supplements opens an avenue for good health through immunomodulation.

Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review

Retrieved on: 
Thursday, June 8, 2023

Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application (IND) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the US Food and Drug Administration on the Company’s Pre-IND submission.

Key Points: 
  • Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application (IND) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the US Food and Drug Administration on the Company’s Pre-IND submission.
  • If successful, that would allow clinical trials to begin by the first half of 2024.
  • The Company’s proprietary, novel technology uses cell- and gene-therapy to promote a renewed immune response against solid tumors.
  • The initial studies have been conducted in a pancreatic cancer mouse model developed and published by Dr. Jewett’s laboratory.

Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board

Retrieved on: 
Thursday, February 16, 2023

Dr. Ahmed’s research has significantly shaped the scientific community’s current understanding of immunity in the context of viral infections and cancer.

Key Points: 
  • Dr. Ahmed’s research has significantly shaped the scientific community’s current understanding of immunity in the context of viral infections and cancer.
  • “We are most excited and honored to have Dr. Ahmed join our SAB,” said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma.
  • We look forward to Rafi’s insights and contributions as we further develop datasets that highlight our differentiated and targeted approach to cancer immunotherapy.”
    Dr. Ahmed, added, “I am delighted to be joining Cue Biopharma’s Scientific Advisory Board.
  • He is also recognized as a Georgia Research Alliance Eminent Scholar and a Fellow of the Academy of Immuno-Oncology.

Frazier Life Sciences Adds Highly Experienced T Cell Immunologist to Team

Retrieved on: 
Wednesday, February 1, 2023

Frazier Life Sciences announced the addition of Bryan A. Irving, Ph.D. as a Senior Advisor.

Key Points: 
  • Frazier Life Sciences announced the addition of Bryan A. Irving, Ph.D. as a Senior Advisor.
  • He has 30 years of experience as a T cell immunologist, including 23 years in the biotech industry focused on discovering and progressing immune drug candidates into the clinic for both autoimmune and oncology indications.
  • His work has been published in top-tier journals including Cell, Science, Cancer Cell, Nature Immunology, and Immunity, and he is an inventor on patents that include the single-chain CARs and atezolizumab.
  • “He is a highly experienced T cell immunologist, and we believe his insights will help us better understand and approach the increasingly complex strategies being pursued in immuno-oncology.”

Ankyra Therapeutics Appoints Leisha A. Emens, M.D., Ph.D., as Senior Vice President, Translational Research

Retrieved on: 
Wednesday, December 7, 2022

Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced that Leisha A. Emens, M.D., Ph.D., has been appointed as senior vice president, translational research.

Key Points: 
  • Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced that Leisha A. Emens, M.D., Ph.D., has been appointed as senior vice president, translational research.
  • With a particular focus on immunotherapy and having held positions at some of the worlds leading academic institutions, Leisha is the ideal person to fill this role.
  • Dr. Emens is a medical oncologist focused on breast cancer and is internationally recognized for her work in breast cancer immunotherapy.
  • Ankyra Therapeutics is a biotechnology company developing a novel approach to treating cancer, designed to expand the therapeutic window of cytokine drugs.

EXUMA Biotech to Present at the 2022 Cancer Immunology and Immunotherapy Conference and to Participate in the 7th Annual CAR-TCR Summit

Retrieved on: 
Friday, September 16, 2022

Additionally, EXUMA will participate in the 7th Annual CAR-TCR Summit organized by Hanson Wade from September 19-22, 2022, in Boston.

Key Points: 
  • Additionally, EXUMA will participate in the 7th Annual CAR-TCR Summit organized by Hanson Wade from September 19-22, 2022, in Boston.
  • "We are encouraged by the progress of EXUMA's novel cell and gene therapy platforms, which have the potential to address current challenges with cellular immunotherapies and provide for the next generation of CAR and TCR-based therapies.
  • EXUMA is using advanced lentivectors designed to generate novel cellular therapeutics to treat cancer patients without the need for preparative, lymphodepleting chemotherapy.
  • 2022 Cancer Immunology and Immunotherapy Conference: Discovery to Mainstream Oncology

Modified bladder cancer treatment shows promise in animal studies

Retrieved on: 
Tuesday, August 23, 2022

SAN ANTONIO, Aug. 23, 2022 /PRNewswire/ -- A modified tuberculosis vaccine developed at Texas Biomedical Research Institute could help treat a form of bladder cancer, called non-muscle invasive bladder cancer, without strong side effects.

Key Points: 
  • SAN ANTONIO, Aug. 23, 2022 /PRNewswire/ -- A modified tuberculosis vaccine developed at Texas Biomedical Research Institute could help treat a form of bladder cancer, called non-muscle invasive bladder cancer, without strong side effects.
  • A modified TB vaccine developed at Texas Biomed could help treat a type of bladder cancer without strong side effects.
  • About 75% of bladder cancer cases are classified as non-muscle invasive, which means the cancer affects the tissue lining the inner surface of the bladder, but not the bladder muscle.
  • Dr. Svatek's lab conducted the tests in a mouse model of bladder cancer and in cells collected from human cancer patients.

CanariaBio Announces Milestone achievement of 50% patient enrollment in its Phase III FLORA-5 clinical study of its lead product oregovomab in front-line advanced ovarian cancer treatment

Retrieved on: 
Thursday, June 30, 2022

For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.

Key Points: 
  • For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.
  • Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in a phase 2 trial.
  • Clinical and translational results were published in Gynecology Oncology 2020 156:523-529) and Cancer Immunology and Immunotherapy 2020 69: 383-397, respectively.
  • CanariaBio Inc. is a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer.